Research programme: beta-lactamase inhibitors - VenatoRx Pharmaceuticals

Drug Profile

Research programme: beta-lactamase inhibitors - VenatoRx Pharmaceuticals

Alternative Names: VNRX 5119; VNRX 5133; VNRX-5113; VRNX 5363

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator VenatoRx Pharmaceuticals
  • Class Antibacterials
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-negative infections

Most Recent Events

  • 09 Nov 2016 VenatoRx Pharmaceuticals and National Institute of Allergy and Infectious Diseases plan a first-in-human phase I trial in Healthy volunteers in USA (IV, Infusion) (NCT02955459)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top